Braidwell LP lifted its position in shares of Vera Therapeutics, Inc. (NASDAQ:VERA – Free Report) by 7.8% during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 564,724 shares of the company’s stock after buying an additional 40,900 shares during the period. Braidwell LP owned about 0.78% of Vera Therapeutics worth $24,232,000 as of its most recent SEC filing.
Other hedge funds also recently bought and sold shares of the company. Los Angeles Capital Management LLC purchased a new position in shares of Vera Therapeutics during the fourth quarter worth approximately $46,000. Quantbot Technologies LP bought a new position in shares of Vera Therapeutics during the 2nd quarter valued at $51,000. Aster Capital Management DIFC Ltd bought a new position in shares of Vera Therapeutics during the 4th quarter valued at $71,000. Nykredit A S purchased a new position in Vera Therapeutics in the 2nd quarter worth $97,000. Finally, Tower Research Capital LLC TRC lifted its stake in Vera Therapeutics by 192.9% in the second quarter. Tower Research Capital LLC TRC now owns 4,186 shares of the company’s stock worth $99,000 after purchasing an additional 2,757 shares during the last quarter. Institutional investors own 99.21% of the company’s stock.
Vera Therapeutics Trading Up 4.2%
NASDAQ VERA opened at $35.66 on Thursday. The firm has a market capitalization of $2.57 billion, a PE ratio of -6.09 and a beta of 0.96. The stock’s 50 day moving average is $36.10 and its 200 day moving average is $37.52. Vera Therapeutics, Inc. has a twelve month low of $21.71 and a twelve month high of $56.05. The company has a quick ratio of 10.92, a current ratio of 10.92 and a debt-to-equity ratio of 0.18.
Analysts Set New Price Targets
VERA has been the topic of several analyst reports. Guggenheim lifted their price objective on Vera Therapeutics from $56.00 to $76.00 and gave the stock a “buy” rating in a report on Wednesday, July 8th. William Blair reaffirmed an “outperform” rating on shares of Vera Therapeutics in a research note on Tuesday, June 2nd. Evercore set a $91.00 price objective on Vera Therapeutics in a research report on Friday, May 15th. Weiss Ratings restated a “sell (d-)” rating on shares of Vera Therapeutics in a report on Friday, July 17th. Finally, Needham & Company LLC set a $125.00 target price on shares of Vera Therapeutics in a research note on Wednesday, July 8th. One research analyst has rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, Vera Therapeutics has a consensus rating of “Moderate Buy” and a consensus price target of $81.15.
View Our Latest Stock Analysis on VERA
Insider Transactions at Vera Therapeutics
In related news, CEO Marshall Fordyce sold 46,250 shares of the business’s stock in a transaction dated Tuesday, July 7th. The shares were sold at an average price of $42.30, for a total transaction of $1,956,375.00. Following the sale, the chief executive officer owned 151,994 shares of the company’s stock, valued at $6,429,346.20. The trade was a 23.33% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 15.90% of the stock is currently owned by company insiders.
Vera Therapeutics Profile
Vera Therapeutics is a clinical-stage biotechnology company focused on developing novel immunotherapies that harness the body’s own regulatory T cells to treat autoimmune and inflammatory diseases. By leveraging a proprietary protein engineering platform, the company designs Treg-selective cytokine variants intended to restore immune balance and provide targeted, disease-modifying effects. Its pipeline comprises multiple preclinical and clinical candidates aimed at indications characterized by chronic inflammation and autoimmunity.
Founded in 2018 and headquartered in Cambridge, Massachusetts, Vera Therapeutics collaborates with leading academic and research institutions to advance its development programs.
Read More
- Five stocks we like better than Vera Therapeutics
- Striking Oil: How the U.S. Play for Venezuela Fuels Supermajors
- J.M. Smucker Stock’s Rally Has More Than Tariffs Behind It
- Wendy’s Rally Fades After Trian Steps Back: Was It Ever Real?
- GitLab’s Earnings Beat Just Gave Software Bulls a New SaaSpocalypse Test
Want to see what other hedge funds are holding VERA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Vera Therapeutics, Inc. (NASDAQ:VERA – Free Report).
Receive News & Ratings for Vera Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vera Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
